Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

192.05SEK
7:36am EDT
Change (% chg)

2.05kr (+1.08%)
Prev Close
190.00kr
Open
188.65kr
Day's High
192.65kr
Day's Low
188.65kr
Volume
315,052
Avg. Vol
826,503
52-wk High
194.75kr
52-wk Low
107.40kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.80
Market Cap(Mil.): kr51,776.46
Shares Outstanding(Mil.): 272.51
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 35.11 29.56 34.14
EPS (TTM): 5.41 -- --
ROI: 16.98 13.56 13.10
ROE: 22.83 15.35 15.09

BRIEF-Sobi appoints Henrik Stenqvist as new CFO

* HENRIK STENQVIST IS JOINING SOBI AS NEW CHIEF FINANCIAL OFFICER

Feb 26 2018

BRIEF-Swedish Orphan Biovitrum says receives positive opinion from CHMP on Anakira

* The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Anakinra for the treatment of Still’s disease.

Feb 23 2018

UPDATE 1-‍Sobi Q4 tops forecast but 2018 outlook below market expectations​

Feb 22 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Thursday a bigger fourth-quarter profit jump than expected but guided for slightly slower profit growth in 2018 than estimated by analysts.

Feb 22 2018

BRIEF-‍Sobi Q4 core profit beats expectations ​

* SAYS ‍SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 7,500 - 7,700 M.​

Feb 22 2018

Earnings vs. Estimates